Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Invuity, Inc.IVTY · Entity 162847 | Director | May 03, 2017 | May 05, 2017 |
| Mobia Medical, Inc.MOBI · Entity 5669 | Director | July 14, 2026 | July 16, 2026 |
| PROCEPT BioRobotics CorpPRCT · Entity 4831 | Director · President, CEO | May 09, 2025 | May 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Invuity, Inc.
Report date May 03, 2017 · Filed May 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,800 |
Reported balance
After 2017-05-03 transaction · row 1
1 source rowRow 1 · 2017-05-03 · Sale · Disposed 4,000 · Balance 8,800 |
Mobia Medical, Inc.
Report date July 14, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $11.57 · Expires 2036-07-14 | Direct | 19,150 |
Reported balance
After 2026-07-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-14 · Grant · Acquired 19,150 · Balance 19,150 F1: The stock option will vest in three substantially equal installments on the first three anniversaries of the grant date. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $11.57 · Expires 2036-07-14 | Direct | 16,260 |
Reported balance
After 2026-07-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-14 · Grant · Acquired 16,260 · Balance 16,260 F2: The stock option will fully vest at the 2027 Annual Meeting, consistent with the Non-Employee Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest in three substantially equal installments on the first three anniversaries of the grant date.
F2: The stock option will fully vest at the 2027 Annual Meeting, consistent with the Non-Employee Director Compensation Policy.
PROCEPT BioRobotics Corp
Report date May 09, 2025 · Filed May 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 186,829 |
Reported balance
After 2025-05-09 transaction · row 1
1 source rowRow 1 · 2025-05-09 · Exercise / conversion · Acquired 13,759 · Balance 186,829 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.27 · Expires 2031-06-21 | Direct | 158,871 |
Reported balance
After 2025-05-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-09 · Exercise / conversion · Disposed 13,759 · Balance 158,871 F1: The Stock option was granted on June 22, 2021 and vests 25% on the six month anniversary of the grant date and the remainder vests on each monthly anniversary over a four year period thereafter, subject continued employment or service to the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock option was granted on June 22, 2021 and vests 25% on the six month anniversary of the grant date and the remainder vests on each monthly anniversary over a four year period thereafter, subject continued employment or service to the Issuer through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AVEDRO INC
Report date November 21, 2019 · Filed November 25, 2019
Section 16 reporting ended · disclosed 2019-11-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-21 transaction · row 1
1 source rowRow 1 · 2019-11-21 · Disposition to issuer · Disposed 18,062 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2019-11-21 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-11-21 · Disposition to issuer · Disposed 315 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share. F2: The reportable securities are held by the Martine and Reza Zadno Revocable Trust. The Reporting Person is a co-trustee and shares voting and investment power. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.73 · Expires 2029-01-08 | Direct | 0 |
Reported balance
After 2019-11-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-21 · Disposition to issuer · Disposed 267,415 · Balance 0 F3: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. Certain of the options may be settled in cash based on the extent, if any, to which the fair market value of the shares underlying the options at the time of exercise exceeds the applicable exercise price of the options. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2028-01-30 | Direct | 0 |
Reported balance
After 2019-11-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-21 · Disposition to issuer · Disposed 525,682 · Balance 0 F3: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. Certain of the options may be settled in cash based on the extent, if any, to which the fair market value of the shares underlying the options at the time of exercise exceeds the applicable exercise price of the options. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.69 · Expires 2028-07-17 | Direct | 0 |
Reported balance
After 2019-11-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-21 · Disposition to issuer · Disposed 200,820 · Balance 0 F3: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. Certain of the options may be settled in cash based on the extent, if any, to which the fair market value of the shares underlying the options at the time of exercise exceeds the applicable exercise price of the options. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-11-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-21 · Disposition to issuer · Disposed 2,103 · Balance 0 F4: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F5: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-11-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-21 · Disposition to issuer · Disposed 76,430 · Balance 0 F4: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F5: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share.
F2: The reportable securities are held by the Martine and Reza Zadno Revocable Trust. The Reporting Person is a co-trustee and shares voting and investment power.
F3: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. Certain of the options may be settled in cash based on the extent, if any, to which the fair market value of the shares underlying the options at the time of exercise exceeds the applicable exercise price of the options.
F4: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F5: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 14, 2026 Filed Jul 16, 2026 23:28 UTC | Mobia Medical, Inc. MOBI · Entity 5669 | GrantStock Option · Derivative | 16,260 | $0.00 Strike: $11.57 | $0.00 |
DisclosureSEC source: 0001193125-26-306432 · ownership.xml · derivative · entry 2 Zadno Reza · CIK 0001632326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,260 Underlying: Common Stock · 16,260 shares Expires 2036-07-14 F2 · derivative.exercise_date: The stock option will fully vest at the 2027 Annual Meeting, consistent with the Non-Employee Director Compensation Policy. Read SEC document |
| July 14, 2026 Filed Jul 16, 2026 23:28 UTC | Mobia Medical, Inc. MOBI · Entity 5669 | GrantStock Option · Derivative | 19,150 | $0.00 Strike: $11.57 | $0.00 |
DisclosureSEC source: 0001193125-26-306432 · ownership.xml · derivative · entry 1 Zadno Reza · CIK 0001632326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,150 Underlying: Common Stock · 19,150 shares Expires 2036-07-14 F1 · derivative.exercise_date: The stock option will vest in three substantially equal installments on the first three anniversaries of the grant date. Read SEC document |
| May 09, 2025 Filed May 13, 2025 20:59 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,759 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001628280-25-025179 · wk-form4_1747169964.xml · derivative · entry 2 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,871 Underlying: Common Stock · 13,759 shares Expires 2031-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Stock option was granted on June 22, 2021 and vests 25% on the six month anniversary of the grant date and the remainder vests on each monthly anniversary over a four year period thereafter, subject continued employment or service to the Issuer through the applicable vesting date. Read SEC document |
| May 09, 2025 Filed May 13, 2025 20:59 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionCommon Stock | 13,759 | $7.27 | $100,027.93 |
DisclosureSEC source: 0001628280-25-025179 · wk-form4_1747169964.xml · nonDerivative · entry 1 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2025 Filed Mar 19, 2025 20:16 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 5,475 | $57.06 | $312,403.50 |
DisclosureSEC source: 0001628280-25-013832 · wk-form4_1742415395.xml · nonDerivative · entry 1 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,070 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average price. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:26 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 15,916 | $61.31 | $975,809.96 |
DisclosureSEC source: 0001628280-25-011700 · wk-form4_1741638404.xml · nonDerivative · entry 1 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,545 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. F2 · price: The price reported in Column 4 is a weighted average price. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:30 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantStock Option (Right to Buy) · Derivative | 36,831 | $0.00 Strike: $60.60 | $0.00 |
DisclosureSEC source: 0001628280-25-010596 · wk-form4_1741213805.xml · derivative · entry 2 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,831 Underlying: Common Stock · 36,831 shares Expires 2035-03-02 F2 · derivative.exercise_date: 1/48th of the shares subject to the Stock Option shall vest monthly from the vesting commencement date of March 5, 2025 over a four year period, subject continued employment or service by the Reporting Person to the Issuer through the applicable vesting date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:30 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock | 41,699 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010596 · wk-form4_1741213805.xml · nonDerivative · entry 1 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,461 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. One-quarter of the RSUs shall vest on March 5, 2026, with one-sixteenth of the remaining RSUs vesting quarterly over 36 months, subject to the Reporting Person continuing as a service provider through such date. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:20 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 2,235 | $99.04 | $221,359.32 |
DisclosureSEC source: 0001628280-24-050224 · wk-form4_1733520032.xml · nonDerivative · entry 4 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,762 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.97 to $99.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:20 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 5,126 | $98.09 | $502,807.80 |
DisclosureSEC source: 0001628280-24-050224 · wk-form4_1733520032.xml · nonDerivative · entry 3 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,997 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.66 to $98.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:20 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 13,762 | $97.01 | $1,335,065.38 |
DisclosureSEC source: 0001628280-24-050224 · wk-form4_1733520032.xml · nonDerivative · entry 2 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,123 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.65 to $97.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:20 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 5,300 | $96.15 | $509,611.96 |
DisclosureSEC source: 0001628280-24-050224 · wk-form4_1733520032.xml · nonDerivative · entry 1 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,885 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.65 to $96.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 21:12 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 1,403 | $99.96 | $140,244.02 |
DisclosureSEC source: 0001628280-24-049561 · wk-form4_1733173968.xml · nonDerivative · entry 4 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 179,185 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.77 to $100.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 21:12 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 5,189 | $99.24 | $514,941.31 |
DisclosureSEC source: 0001628280-24-049561 · wk-form4_1733173968.xml · nonDerivative · entry 3 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,588 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.75 to $99.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 21:12 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 1,684 | $98.00 | $165,033.85 |
DisclosureSEC source: 0001628280-24-049561 · wk-form4_1733173968.xml · nonDerivative · entry 2 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.74 to $98.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 21:12 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 18,144 | $97.25 | $1,764,418.72 |
DisclosureSEC source: 0001628280-24-049561 · wk-form4_1733173968.xml · nonDerivative · entry 1 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,461 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.74 to $97.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:07 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 500 | $93.88 | $46,942.00 |
DisclosureSEC source: 0001628280-24-048972 · wk-form4_1732309658.xml · nonDerivative · entry 3 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,605 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.62 to $94.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:07 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 15,809 | $92.82 | $1,467,350.28 |
DisclosureSEC source: 0001628280-24-048972 · wk-form4_1732309658.xml · nonDerivative · entry 2 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,105 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.51 to $93.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:07 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 10,111 | $92.12 | $931,431.39 |
DisclosureSEC source: 0001628280-24-048972 · wk-form4_1732309658.xml · nonDerivative · entry 1 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 221,914 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.51 to $92.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:28 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 4,510 | $95.58 | $431,074.37 |
DisclosureSEC source: 0001628280-24-048105 · wk-form4_1731706118.xml · nonDerivative · entry 4 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 232,025 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.31 to $96.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:28 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 9,401 | $94.95 | $892,630.59 |
DisclosureSEC source: 0001628280-24-048105 · wk-form4_1731706118.xml · nonDerivative · entry 3 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 236,535 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.31 to $95.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:28 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 2,000 | $93.64 | $187,277.80 |
DisclosureSEC source: 0001628280-24-048105 · wk-form4_1731706118.xml · nonDerivative · entry 2 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 245,936 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.30 to $94.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:28 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 10,509 | $92.74 | $974,589.95 |
DisclosureSEC source: 0001628280-24-048105 · wk-form4_1731706118.xml · nonDerivative · entry 1 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 247,936 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 8, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.26 to $93.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 30, 2024 Filed Oct 31, 2024 21:07 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionStock Option (Right to Buy) · Derivative | 288,461 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001628280-24-044595 · wk-form4_1730408825.xml · derivative · entry 3 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 961,148 Underlying: Common Stock · 288,461 shares Expires 2030-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Stock option was granted on February 20, 2020, and vested over a four year period. Read SEC document |
| October 30, 2024 Filed Oct 31, 2024 21:07 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 288,461 | $91.00 | $26,249,951.00 |
DisclosureSEC source: 0001628280-24-044595 · wk-form4_1730408825.xml · nonDerivative · entry 2 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 258,445 F1 · kind: Shares sold on October 30, 2024, pursuant to the underwriters exercise of an option to purchase shares as detailed in the prospectus supplement filed with the SEC, dated October 29, 2024, pursuant to Rule 424(b)(5) and Registration No. 333-273569. Read SEC document |
| October 30, 2024 Filed Oct 31, 2024 21:07 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionCommon Stock | 288,461 | $4.37 | $1,260,574.57 |
DisclosureSEC source: 0001628280-24-044595 · wk-form4_1730408825.xml · nonDerivative · entry 1 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 546,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2024 Filed Aug 23, 2024 20:19 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,484 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001628280-24-038355 · wk-form4_1724444339.xml · derivative · entry 2 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,249,609 Underlying: Common Stock · 23,484 shares Expires 2030-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Stock Option was granted on February 20, 2020 and vested over a four year period. Read SEC document |
| July 31, 2024 Filed Aug 23, 2024 20:19 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionCommon Stock | 23,484 | $4.37 | $102,625.08 |
DisclosureSEC source: 0001628280-24-038355 · wk-form4_1724444339.xml · nonDerivative · entry 1 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 258,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 20:46 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 5,391 | $48.83 | $263,242.53 |
DisclosureSEC source: 0001628280-24-012237 · wk-form4_1710967550.xml · nonDerivative · entry 1 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,319 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on March 31, 2022. F2 · price: The price reported in Column 4 is a weighted average price. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 00:50 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantStock Option (Right to Buy) · Derivative | 47,849 | $0.00 Strike: $47.17 | $0.00 |
DisclosureSEC source: 0001628280-24-009763 · wk-form4_1709859047.xml · derivative · entry 3 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,849 Underlying: Common Stock · 47,849 shares Expires 2034-03-05 F4 · derivative.exercise_date: 1/48th of the shares subject to the Stock Option shall vest monthly from the vesting commencement date of March 5, 2024 over a four year period, subject continued employment or service by the Reporting Person to the Issuer through the applicable vesting date. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 00:50 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 9,179 | $46.67 | $428,383.93 |
DisclosureSEC source: 0001628280-24-009763 · wk-form4_1709859047.xml · nonDerivative · entry 2 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,710 F2 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on February 16, 2023. F3 · price: The price reported in Column 4 is a weighted average price. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 00:50 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock | 54,933 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-009763 · wk-form4_1709859047.xml · nonDerivative · entry 1 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,889 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. 1/4th of the RSUs shall vest on the anniversary of the vesting commencement date of March 5, 2024, and annually over a three year period thereafter, subject to continued employment or service by the Reporting Person to the Issuer through the applicable vesting date. Read SEC document |
| March 06, 2024 Filed Apr 19, 2024 23:06 UTC Amendment | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantStock Option (Right to Buy) · Derivative | 42,311 | $0.00 Strike: $47.17 | $0.00 |
DisclosureSEC source: 0001628280-24-017006 · wk-form4a_1713567994.xml · derivative · entry 2 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,311 Underlying: Common Stock · 42,311 shares Expires 2034-03-05 F3 · shares: This Form 4 amendment corrects a clerical error in the number of shares underlying the stock option granted to the reporting person on March 6, 2024. F4 · derivative.exercise_date: 1/48th of the shares subject to the Stock Option shall vest monthly from the vesting commencement date of March 5, 2024 over a four year period, subject continued employment or service by the Reporting Person to the Issuer through the applicable vesting date. Read SEC document |
| March 06, 2024 Filed Apr 19, 2024 23:06 UTC Amendment | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock | 48,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-017006 · wk-form4a_1713567994.xml · nonDerivative · entry 1 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,531 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. 1/4th of the RSUs shall vest on the anniversary of the vesting commencement date of March 5, 2024, and annually over a three year period thereafter, subject to continued employment or service by the Reporting Person to the Issuer through the applicable vesting date. F2 · shares: This Form 4 amendment corrects a clerical error in the number of shares of common stock granted in the form of RSUs to the reporting person on March 6, 2024. The incorrect total common stock share amount was also reported in one subsequent transaction on the original Form 4, and one subsequent Form 4 filed by the reporting person after the original Form 4 was filed. Read SEC document |
| October 18, 2023 Filed Oct 18, 2023 20:28 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,148 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001628280-23-034592 · wk-form4_1697660875.xml · derivative · entry 2 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,273,093 Underlying: Common Stock · 5,148 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Stock option was granted on February 20, 2020 and vests 25% on the anniversary of the vesting commencement date of February 1, 2020 and the remaining shares vest on each monthly anniversary over a 3 year period thereafter, subject continued employment or service to the Issuer through the applicable vesting date. Read SEC document |
| October 18, 2023 Filed Oct 18, 2023 20:28 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionCommon Stock | 5,148 | $4.37 | $22,496.76 |
DisclosureSEC source: 0001628280-23-034592 · wk-form4_1697660875.xml · nonDerivative · entry 1 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2023 Filed May 2, 2023 21:13 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,995 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001588978-23-000014 · wf-form4_168306198426245.xml · derivative · entry 2 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,278,241 Underlying: Common Stock · 19,995 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Stock option was granted on February 20, 2020 and vests 25% on the anniversary of the vesting commencement date of February 1, 2020 and the remaining shares vest on each monthly anniversary over a 3 year period thereafter, subject continued employment or service to the Issuer through the applicable vesting date. Read SEC document |
| April 28, 2023 Filed May 2, 2023 21:13 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionCommon Stock | 19,995 | $4.37 | $87,378.15 |
DisclosureSEC source: 0001588978-23-000014 · wf-form4_168306198426245.xml · nonDerivative · entry 1 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2023 Filed Apr 5, 2023 21:33 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,022 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001628280-23-010897 · wf-form4_168073036847237.xml · derivative · entry 2 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,298,236 Underlying: Common Stock · 20,022 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Stock option was granted on February 20, 2020 and 25% of the Stock option vests on the first anniversary of February 1, 2020, the vesting commencement date, and the remaining shares vest on each monthly anniversary over a 3 year period thereafter, subject to continued employment or service to the Issuer through the applicable vesting date. Read SEC document |
| April 04, 2023 Filed Apr 5, 2023 21:33 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | Exercise / conversionCommon Stock | 20,022 | $4.37 | $87,496.14 |
DisclosureSEC source: 0001628280-23-010897 · wf-form4_168073036847237.xml · nonDerivative · entry 1 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 19:55 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | SaleCommon Stock | 5,335 | $31.84 | $169,866.40 |
DisclosureSEC source: 0001628280-23-008461 · wf-form4_167908290315435.xml · nonDerivative · entry 1 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,791 F1 · shares: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on March 31, 2022. F2 · price: The price reported in Column 4 is a weighted average price. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:38 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantStock Option (Right to Buy) · Derivative | 119,332 | $0.00 Strike: $37.02 | $0.00 |
DisclosureSEC source: 0001628280-23-004330 · wf-form4_167701547739856.xml · derivative · entry 2 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,332 Underlying: Common Stock · 119,332 shares Expires 2033-02-15 F2 · derivative.exercise_date: 1/48th of the shares subject to the Stock Option shall vest monthly from the vesting commencement date of March 5, 2023 over a four year period, subject continued employment or service by the Reporting Person to the Issuer through the applicable vesting date. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:38 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock | 65,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-004330 · wf-form4_167701547739856.xml · nonDerivative · entry 1 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,126 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. 1/4th of the RSUs shall vest on the anniversary of the vesting commencement date of March 5, 2023, and annually over a three year period thereafter, subject to continued employment or service by the Reporting Person to the Issuer through the applicable vesting date. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:18 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantStock Option (Right to Buy) · Derivative | 79,584 | $0.00 Strike: $34.99 | $0.00 |
DisclosureSEC source: 0001628280-22-008264 · wf-form4_164910710920613.xml · derivative · entry 2 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,584 Underlying: Common Stock · 79,584 shares Expires 2032-03-30 F2 · price: The Stock option was granted on March 31, 2022 and vests 1/48th on the anniversary of the vesting commencement date of March 15, 2022, and monthly over a four year period thereafter, subject continued employment or service to the Issuer through the applicable vesting date. F2 · derivative.exercise_date: The Stock option was granted on March 31, 2022 and vests 1/48th on the anniversary of the vesting commencement date of March 15, 2022, and monthly over a four year period thereafter, subject continued employment or service to the Issuer through the applicable vesting date. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:18 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | GrantCommon Stock | 39,312 | $29.38 | $1,154,986.56 |
DisclosureSEC source: 0001628280-22-008264 · wf-form4_164910710920613.xml · nonDerivative · entry 1 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,337 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. One-quarter of the RSUs shall vest on March 15, 2023, with one-quarter of the remaining RSUs vesting annually on each of the second, third, and fourth anniversary thereof, subject to the Reporting Person continuing as a service provider through such date. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 22:35 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | ConversionSeries F Convertible Preferred Stock · Derivative | 3,394 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001628280-21-018956 · wf-form4_163226370809997.xml · derivative · entry 2 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,394 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock will convert automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date. F1 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock will convert automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock will convert automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock will convert automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 22:35 UTC | PROCEPT BioRobotics Corp PRCT · Entity 4831 | ConversionCommon Stock | 3,394 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-21-018956 · wf-form4_163226370809997.xml · nonDerivative · entry 1 Zadno Reza · CIK 0001632326 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock will convert automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 21:38 UTC | AVEDRO INC AVDR · Entity 153528 | Disposition to issuerRestricted Stock Units · Derivative | 76,430 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-057946 · doc4.xml · derivative · entry 7 Zadno Reza · CIK 0001632326 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,430 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F5 · price: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU. F5 · derivative.exercise_date: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU. F5 · derivative.expiration_date: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 21:38 UTC | AVEDRO INC AVDR · Entity 153528 | Disposition to issuerRestricted Stock Units · Derivative | 2,103 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-057946 · doc4.xml · derivative · entry 6 Zadno Reza · CIK 0001632326 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,103 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F5 · price: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU. F5 · derivative.exercise_date: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU. F5 · derivative.expiration_date: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 21:38 UTC | AVEDRO INC AVDR · Entity 153528 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 200,820 | Not disclosed Strike: $3.69 | Not disclosed |
DisclosureSEC source: 0001209191-19-057946 · doc4.xml · derivative · entry 5 Zadno Reza · CIK 0001632326 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,820 shares Expires 2028-07-17 F3 · price: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. Certain of the options may be settled in cash based on the extent, if any, to which the fair market value of the shares underlying the options at the time of exercise exceeds the applicable exercise price of the options. F3 · derivative.exercise_date: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. Certain of the options may be settled in cash based on the extent, if any, to which the fair market value of the shares underlying the options at the time of exercise exceeds the applicable exercise price of the options. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.